| 1 WOMAC pain (0‐20 Likert) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 1.1 45 to 52 weeks post‐injection |
1 |
254 |
Mean Difference (IV, Fixed, 95% CI) |
‐3.16 [‐4.17, ‐2.15] |
| 2 WOMAC pain (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 2.1 36 weeks post‐injection |
1 |
497 |
Mean Difference (IV, Fixed, 95% CI) |
‐12.70 [‐16.41, ‐8.99] |
| 3 Pain on walking (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 3.1 36 weeks post‐injection |
1 |
506 |
Mean Difference (IV, Fixed, 95% CI) |
‐12.10 [‐16.05, ‐8.15] |
| 4 WOMAC function (0‐68 Likert) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 4.1 45 to 52 weeks post‐injection |
1 |
231 |
Mean Difference (IV, Fixed, 95% CI) |
‐9.61 [‐13.09, ‐6.13] |
| 5 WOMAC function (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 5.1 36 weeks post‐injection |
1 |
498 |
Mean Difference (IV, Fixed, 95% CI) |
‐13.20 [‐17.02, ‐9.38] |
| 6 Lequesne Index (0‐24) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 6.1 36 weeks post‐injection |
1 |
506 |
Mean Difference (IV, Fixed, 95% CI) |
‐2.20 [‐2.98, ‐1.42] |
| 7 WOMAC total score (0‐100 mm VAS) |
1 |
|
Mean Difference (IV, Fixed, 95% CI) |
Subtotals only |
| 7.1 36 weeks post‐injection |
1 |
495 |
Mean Difference (IV, Fixed, 95% CI) |
‐13.20 [‐16.92, ‐9.48] |
| 8 Patient global assessment (number of patients improved in study knee) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9 Patient global evaluation of effectiveness (good or satisfactory) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 9.1 36 weeks post‐injection |
1 |
506 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.44 [1.25, 1.66] |
| 10 Number of responders (20% decrease in pain on walking) |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 10.1 36 weeks post‐injection |
1 |
506 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.30 [1.18, 1.43] |
| 11 Safety: total withdrawals overall |
2 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 12 Safety: wIthdrawals due to lack of effectiveness |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 13 Safety: wIthdrawals due to adverse events |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 14 Safety: number of patients reporting mild, moderate or severe side effects at month 12 |
1 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
| 15 Safety: total number of patients reporting side effects from baseline |
2 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 16 Safety: number of patients with gastrointestinal adverse events |
2 |
|
Risk Ratio (M‐H, Fixed, 95% CI) |
Subtotals only |
